STAQ Pharma, Inc., Denver, CO
Is STAQ Pharma, Inc. registered with the FDA as a 503B outsourcing facility?
Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names STAQ Pharma, Inc. in Denver, CO, first registered Feb 5, 2019 and most recently registered Dec 18, 2025.
Does STAQ Pharma, Inc. hold a Colorado pharmacy license?
No license with this exact name and city was found in the Colorado State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The California State Board of Pharmacy also lists nonresident license NSF 143 for Staq Pharma Inc, Denver, CO, status Active, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0010077 for STAQ Pharma, Inc., DENVER, CO, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012624 for STAQ Pharma, Inc., Denver, CO, status Active, as of Nov 10, 2026.
Has STAQ Pharma, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 3 FMD-145 letters (May 25, 2021, Mar 25, 2022 and Jun 6, 2025) for STAQ Pharma, Inc. State board actions: no Colorado State Board of Pharmacy action under this exact name and city was found in the board’s license dataset (actions dated Oct 11, 1985 to Oct 30, 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- STAQ Pharma, Inc.
- Location
- Denver, CO
- Type as FDA labels it
- 503B
- FDA 503B list
- Listed as STAQ Pharma, Inc.
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jun 6, 2025
- FDA Data Dashboard inspections
- 3 inspections: 3 VAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 5 observations
- State board records
- No exact match
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as STAQ Pharma, Inc., a 503B facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Jun 6, 2025 | FMD-145 letter | FMD-145 Letter Issued 06/06/2025 | Not linked by FDA |
| Mar 25, 2022 | FMD-145 letter | FMD-145 Letter Issued 03/25/2022 | Not linked by FDA |
| Sep 29, 2021 | Form 483 | 483 Issued 09/29/2021 | FDA copy (archived) |
| May 25, 2021 | FMD-145 letter | FMD-145 Letter Issued 05/25/2021 | Not linked by FDA |
| Sep 3, 2020 | Form 483 | 483 Issued 09/03/2020 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists STAQ Pharma, Inc., Denver, CO (FEI number 3015144909), matched to this page by exact name, city and state. It lists 3 inspections: 3 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 10, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015144909 | 1262991 |
| Sep 29, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015144909 | 1155181 |
| Sep 3, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015144909 | 1128435 |
Form 483s FDA has published for this site
- Sep 29, 2021: Form 483 to STAQ Pharma, Inc., published May 26, 2022. fda.gov
- Sep 3, 2020: Form 483 to STAQ Pharma, Inc., published Nov 2, 2020. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 25, 2020 to Sep 3, 2020: 5 observations
- Firm on the cover
- STAQ Pharma, Inc., 14135 E 42nd Ave Ste 50, Denver, CO 80239-5214
- FEI number
- 3015144909
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 6th & Kipling St. (P. 0. Box 25087) Denver, CO 80225-0087
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
For example:
a) An investigation (DEV 20-020, July 2020) concerning the leaking of finished and filled syringes in Ketamine HCL 10 mg/ml, 5 ml in a 5 ml syringe lot <Redacted B4> discovered during visual inspection of filled drug product, did not fully pursue root cause to determine adequacy of container and closure system integrity for marketed sterile drug products and specifically why filled syringes were found leaking. Per the investigation, "The most probable root cause for product leaking beyond the plunger stoppers in <Redacted B4> syringes for lot <Redacted B4> is materials [the syringe]." ... " [STAQ] Method and machine1y are possible contiibuting factors ... " ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
For example:
a) The Smoke Study performed in Production Room D is not adequate to show production areas have unidirectional airflow, as the Study shows detection of some instances where there is turbulence.
I) The Smoke Study in the ISO 5 hood in Room D shows that air (smoke) rises towards the ceiling in areas adjacent to the ISO 5 Hood instead of cascading towards the floor where uptakes are located, indicating turbulence instead of unidirectional airflow. Turbulence is also indicated in areas where ISO 5 air meets ISO 7 air.
II) The ISO 7 area, where the ISO 5 hood is located, was not folly included in the Smoke Study to demonstrate air flow adequacy and impact on the ISO 5 environment. The hood generates <Redacted B4> directed (ISO 5) air and is open to the ISO 7 environment. which produces vertically (downward) flowing air.
The Smoke Study video shows the following from the hood in Production Room D:
i) At 00:37-00:40 there is turbulence
ii) At 00:50-00:54 there is turbulence ...
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
For example:
a) Media plates used for detecting microbes (in ISO 5 hood areas during filling) with active air sampling do not contain neutralizing agents to ensure detection and growth of microbes in the presence of disinfecting agents utilized in the filling room.
b) There is no environmental monitoring of aseptic setup in ISO 5 hood areas, i.,e., no viable (air and personnel) and no paiticle monitoring.
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning an ddisinfecting the room and equipment to produce aseptic conditions.
Specifically, classified area disinfecting procedures (SOP 201 Classified Area Cleaning) do not ensure contact times are accomplished, there is no contact time established for <Redacted B4> and there is nothing in the procedure determining how much area can be wiped with a single mop surface or hand wipe surface. For example, it was observed on 8/27/2020, as a regular practice, that the Operator used the same hand wipe surface to disinfect multiple production surfaces within the same ISO area.
Observation 5
The labels of your outsourcing facility's drug products are deficient.
The templated labels received of your outsourcing facility's drug products does not include information required by section 503B(a)(l0)(A) and 503B(a)(l0)(B) . Specifically, the dosage form of the product, such as "Injection" for the IV formulations, was missing. Some examples include:
Fentanyl Citrate 100 mcg/2ml
Fentanyl Citrate 250 mcg/5ml
Fentanyl Citrate 1000 mcg/20ml
Hydromorphone HCL 0.4mg/2ml
Hydromorphone HCL 2mg/10ml
Ketamine HCL 50mg/5ml
Ketamine HCL 30mg/3ml
Midazolam 2mg/2ml
Midazolam 25mg/25ml
Morphine Sulfate 2mg/2ml
Morphine Sulfate 5mg/5ml
Linked 483s whose text is not shown
- Sep 29, 2021: FDA document 158588: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
No license with this exact name and city was found in the Colorado State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.
What this covers: Discipline the Department of Regulatory Agencies publishes with each license in the dataset (case number, program action and effective date), worded as the department gives it. Actions in the data are dated Oct 11, 1985 to Oct 30, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NSF 143 | Nonresident Outsourcing Facility | Staq Pharma Inc | Denver, CO | Active |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0010077 | Outsourcing Facility-Distributor | STAQ Pharma, Inc. | DENVER, CO | Active |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301012624 | Pharmacy | STAQ Pharma, Inc. | Denver, CO | Active |
FDA’s 503B list
- STAQ Pharma, Inc., Denver, CO: last inspection Sep 8, 2026, Form 483 at that inspection: Yes, action FDA lists: Open.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Colorado State Board of Pharmacy license file
- California State Board of Pharmacy license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.